GlaxoSmithKline PLC (GSK) shares surged 5.31% in pre-market trading Tuesday, driven by a robust second-quarter earnings report that handily beat analyst expectations and promising pipeline news.

The company reported adjusted earnings per share of $1.35, surpassing the consensus estimate of $1.27 by 6.3%, while quarterly sales of $11.28 billion topped the $10.79 billion forecast. The results represent a nearly 9% increase in earnings and a 5.8% rise in sales compared to the same period last year. GSK also reaffirmed its 2026 guidance, expecting core EPS growth of 7% to 9% and turnover growth of 3% to 5%.

Adding to the positive momentum, GSK’s licensor Hansoh Pharma reported positive phase III data from the ARTEMIS-011 trial of risvantinostat, a B7-H3 targeted drug, in osteosarcoma, bolstering confidence in the company’s oncology pipeline. The company also announced a new cost-cutting plan and a ‘Accelerate Growth’ program, alongside plans to build a new R&D center in Cambridge, further supporting long-term growth prospects.